Oncology Medical News about Pegylated interferons

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma
European Journal of Cancer, 10/29/09

Kaehler KC et al. – The role of pegylated interferons in the setting of advanced metastatic melanoma will need further investigation in clinical trials, potentially in combination with targeted or cytotoxic agents with regard to synergistic antiangiogenic and cytotoxic effects. The use of pegylated interferons in earlier stage melanomas will be investigated in upcoming trials.

<< Previous
Chemoradiotherapy for locally advanced head and neck cancer:...

Next >>
Racial differences in follow-up of abnormal mammography findings...

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
Hepatology, 10/26/09 Relevance Score: 66%

High Levels of Chronic Immune Activation in the T-Cell Compartments of Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1 and on Highly Active Antiretroviral Therapy Are Reverted by Alpha Interferon and Ribavirin Treatment
Journal of Virology, 10/19/09 Relevance Score: 65%

Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection
Clinical and Experimental Dermatology, 10/16/09 Relevance Score: 65%

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Journal of Clinical Oncology, 10/16/09 Relevance Score: 64%

Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-Infected and HIV-Uninfected Patients
Clinical Infectious Diseases, 10/16/09 Relevance Score: 64%